Applied down by a third on latest galactosaemia stumble

US biopharma Applied Therapeutics (Nasdaq: APLT) has suffered another setback in its development of AT-007 in galactosemia.

There are currently no approved treatments for the disease, which is a rare, hereditary disorder of carbohydrate metabolism that affects the body's ability to convert galactose to glucose.

After 12 months of treatment, the use of AT-007 has failed to show statistical significance in the ACTION-Galactosemia Kids Phase III trial, thereby failing to meet the study’s primary endpoint.